BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

We think our checkpoint inhibitor lorigerlimab differentiates well because we specifically target the T cells that are ...

Updates on Proprietary Investigational Programs Lorigerlimab is a bispecific, tetravalent PD-1 × CTLA-4 DART ® molecule designed to enhance ... have been relatively insensitive to checkpoint inhibitor ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.

So, by hindering these proteins, checkpoint inhibitors allow the immune system to attack the cancer cells. The most common checkpoint proteins that these drugs target are PD-1, PD-L1, CTLA-4, and ...